|
Sub-category:
Other Novel Therapies
Category:
Biologic and Targeted Therapies
Meeting:
2002 ASCO Annual Meeting
Abstract No:
51
Citation:
Proc Am Soc Clin Oncol 21: 2002 (abstr 51)
Author(s):
Nancy L Bartlett, Tom E Witzig, Leo Gordon, Thomas Beck, Louis Fehrenbacher, Ellen Kornmehl, Richard Levy, Lewis N Terry, James L Murray, Andrew Raubitschek, Katie Vo, Christine A White, Washington Univ, St Louis, MO; Mayo Clinic, Rochester, MN; Northwestern University, Robert H. Lurie Cancer Center, Chicago, IL; Mountain States Tumor Institute, Boise, ID; Kaiser Permanente Medical Center, Vallejo, CA; Harvard, Boston, MA; Jewish Hospital Kenwood, Cincinnati, OH; Greenville Hospital System, Greenville, SC; M.D. Anderson Cancer Center, Houston, TX; City of Hope Natl Medcl Ctr, Duarte, CA; IDEC Pharmaceuticals Corp, San Diego, CA.
Abstract:
Ibritumomab is a murine antiùCD20 monoclonal antibody covalently bound to tiuxetan, which strongly chelates 90Yttrium or 111Indium. Treatment involves rituximab on day 1 and 8 followed by 111Inùibritumomab tiuxetan 5 mCi for imaging on day 1 and 90Yùibritumomab tiuxetan 0.3 mCi/kg (platelets 100 ù 150k/mm3) or 0.4 mCi/kg (platelets > 150k/mm3) on day 8. Fifteen patients with indolent Bùcell NHL which transformed to a higher grade were treated in 4 trials. The common inclusion criteria of these trials include < 25% bone marrow involvement, ANC > 1,500/mm3 and no prior myeloablative therapy. Median age was 60 (35ù76) yrs; median of 2 prior therapies (range 1ù5); 67% BM involvement; 27% splenomegaly; 80% > 5cm, 27% >7cm, 20% > 10cm. The 179 patients who underwent central dosimetry review had acceptable biodistribution and estimated radiation absorbed doses to normal organs. Toxicity was primarily hematologic. Gr 4 neutropenia and thrombocytopenia occurred in 40% and 20%. Overall response rate, by International Workshop NHL Response Criteria, was 53% (13%CR, 40%PR). Median time to progression in responders was 8.5 (2.1ù37.2+) months. Two patients (13%) are still in remission at 30.6+ and 37.2+ months. This preliminary evidence suggests ibritumomab tiuxetan is safe and effective in patients with transformed Bùcell NHL.
 Associated Presentation(s):
Other Abstracts in this Sub-Category:
Abstracts by Nancy L Bartlett:
Presentations by Nancy L Bartlett:
Educational Book Manuscripts by Nancy L Bartlett:
|
